About Us
Introducing APT Oncology
APT Oncology is a groundbreaking joint venture between AmplifyBio and Pathfinder Oncology, dedicated to advancing personalized TCR-T therapies for oncology patients. By leveraging AmplifyBio’s clinically validated TCR therapy platform, scalable manufacturing capabilities, and Pathfinder Oncology’s immuno-oncology and patient journey expertise, APT Oncology aims to create novel, patient-specific T-cell therapies for advanced solid tumors. This collaboration combines the strengths of both companies to drive the development and production of personalized neoantigen TCR-T cell therapies, offering a significant advancement in personalized cancer treatment.
2021
AmplifyBio Launch
AmplifyBio is launched from Battelle to accelerate the development of advanced therapies through discovery, safety, and manufacturing services.
2022
Platform IP Acquired
AmplifyBio acquires from PACT Pharma intellectual property for developing safety validated, novel, neoantigen-targeted T-Cell therapeutics
2024
Pathfinder Oncology Launch
Pathfinder was founded to create data-driven, patient-centered pathways that provide the best chance for exceptional outcomes in advanced cancer.
2025
APT Oncology JV Launch
APT Oncology formed as a shared commitment to accelerating access to personalized immunotherapies through leveraging the know-how of both companies.
About AmplifyBio
AmplifyBio is a preclinical CRO and CDMO organization founded on the principle that all development and scale-up of advanced modality drugs should be done with commercial and clinical goals in mind. AmplifyBio launched with an initial offering of industry-leading preclinical toxicology, safety, and efficacy testing in an agile environment with analytics capabilities that serve the dynamic safety requirements of modern modalities. Since then, they have developed drug discovery and characterization service capabilities, including acquiring TCR therapeutic discovery patents from PACT Pharma and opening a GMP manufacturing facility to provide complete concept-to-commercial partnerships for commercializing advanced therapies.
About Pathfinder Oncology
Pathfinder was founded to create data-driven, patient-centered pathways that provide the best chance for exceptional outcomes in advanced cancer. We collaborate with leading healthcare professionals, medical researchers, and patient advocacy organizations to bridge the gap between innovation and patient care.
Have additional questions?
We’re here to help. Let’s talk.